L3VLUP
ProSign in

TMO · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TMOVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TMO
  • VRTX
0204060202120222023202420252026
Holders and value by quarter
QuarterTMOVRTX
Q3 202029 holders, $38.9bn31 holders, $21.9bn
Q4 202033 holders, $39.2bn30 holders, $18.4bn
Q1 202135 holders, $36.5bn31 holders, $15.4bn
Q2 202133 holders, $38.3bn30 holders, $12.7bn
Q3 202132 holders, $42.6bn35 holders, $10.1bn
Q4 202138 holders, $50.1bn28 holders, $12.4bn
Q1 202232 holders, $43.2bn23 holders, $16.1bn
Q2 202233 holders, $38.9bn25 holders, $18.1bn
Q3 202226 holders, $34.3bn22 holders, $18.4bn
Q4 202229 holders, $37.0bn28 holders, $18.4bn
Q1 202335 holders, $37.1bn26 holders, $21.4bn
Q2 202339 holders, $33.5bn27 holders, $24.7bn
Q3 202339 holders, $32.6bn33 holders, $24.3bn
Q4 202341 holders, $32.7bn32 holders, $28.6bn
Q1 202430 holders, $34.1bn31 holders, $29.8bn
Q2 202438 holders, $30.6bn29 holders, $33.4bn
Q3 202430 holders, $33.8bn27 holders, $33.5bn
Q4 202436 holders, $27.6bn26 holders, $28.5bn
Q1 202531 holders, $24.2bn21 holders, $35.4bn
Q2 202539 holders, $18.8bn21 holders, $32.3bn
Q3 202532 holders, $21.9bn22 holders, $25.9bn
Q4 202532 holders, $29.9bn26 holders, $31.8bn
Q1 202634 holders, $24.4bn25 holders, $31.8bn
Q2 202636 holders, $26.4bn26 holders, $34.6bn
TMO

Thermo Fisher Scientific Inc

Holders
39
Reported value
$18.8bn
Buyers
27
Sellers
11

Breadth +16 among 95 comparable managers.

IndustrialsHealthcare: biopharma and medtech · L3VLUPIndustrials and automation · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
21
Reported value
$32.3bn
Buyers
11
Sellers
11

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TMO (24)

Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Farallon Capital Management LLC, Glenview Capital Management LLC, Jane Street Group LLC, Markel Group Inc, Millennium Management LLC, Point72 Asset Management LP, Polen Capital Management LLC, Quantbot Technologies LP, Rokos Capital Management LLP, Schonfeld Strategic Advisors LLC, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC, Winton Group Ltd

Only VRTX (6)

AQR Capital Management LLC, ARK Investment Management LLC, Bridgewater Associates LP, Hudson Bay Capital Management LP, Man Group PLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →